Drug Interactions Expert Witnesses

This qualified expert has been involved in the field of medical technologies for over forty years and is experienced with matters concerning FDA compliance on which he has authored several articles and papers and given talks on FDA compliance worldwide. He is also the vice president of a private medical technologies firm, making him intimately qualified to comment on the case at hand.

This highly-qualified expert has 45 years of experience in the field of security and risk management. His areas of expertise include premises liability, nightclub security, security guards, apartment properties, retail loss prevention, negligent hiring/retention and cargo losses due to inadequate security. He earned his BA in sociology with an emphasis in criminology from Louisiana State University. This expert is active in his field as a member of the American Society for Industrial Security, as an author of several published security articles, and a speaker at various security conferences. He began his career with Southern Research Company, serving as a security guard supervisor and as part of the investigations division working on theft and narcotics investigation. He then went on to serve as a patrol officer with the Dallas Police Department and the single unit and area loss prevention manager for Sears. For 12 years, he worked with Eckerd Corporation, serving first as a regional loss prevention manager before becoming the director of loss prevention operations. For nearly 20 years, this expert has served as the president of his risk analysis and security management consulting firm in Texas.

This expert isProfessor and Head of the Department of Health Outcomes Research and Policy at a major university school of pharmacy. He holds a bachelors degree in pharmacy from the University of Wisconsin, and a PhD in Social, Administrative, and Clinical Pharmacy from the University of Minnesota. Prior to joining Auburn University he was Associate Professor of Pharmaceutical Outcomes and Policy in the Eshelman School of Pharmacy at the University of North Carolina. This expert’s research focuses population-level assessment of the benefits and risks of drug treatments. His work has been funded by numerous organizations, including the National Institutes of Health, the Agency for Healthcare Research and Quality, the Foundation for the National Institutes of Health, the National Pharmaceutical Council, and the U.S. Food and Drug Administration. He has worked extensively in the area of comparative effectiveness research and drug safety, and teaches classes related to this work.

This expert has over 30-years of experience in law enforcement, primarily with the Drug Enforcement Administration. He has written three criminal justice textbooks. He currently serves as a Criminal Justice consultant and expert witness with extensive experience in litigation support.

This expert has over 30 years of experience in law enforcement with 20 of those years in the Drug Enforcement Administration. At the DEA, he worked in various positions including Resident Agent in Charge and Inspector. He currently owns a consulting & investigative services firm and works as a Private Investigator specializing in Consulting and Private and Executive Securities.

This expert is a pharmacist and a pharmacologist and a former professor at Yale University and Georgetown University. He is also a former FDA Medical Officer/Senior Medical Analyst, who is an expert in the areas of drug Safety, drug development, regulatory affairs and FDA policy. He as also served as an advisor on the 2016 Ted Cruz presidential campaign, and has also been invited to testify in front of the U.S. Senate as a healthcare policy expert, FDA expert and Pharmacology expert. He has authored or co-authored over 50 publications, papers, articles, reviews, clinical protocols and reports in many related areas including FDA law, drug pricing, healthcare policy, healthcare insurance, drug development and drug patent law.

This expert's research career has been focused in the area of drug safety. As a clinical epidemiologist and pharmacologist, he uses large administrative databases in Canada and the United States as the main data source for his research. In the last ten years he has made significant contributions to this area quantifying rare drug adverse events with popular prescription drugs. His research has been used by the FDA, Health Canada and European Medicines Agency

This highly qualified expert has years of experience in using animal models to study diabetes. He received his PhD degree from Ohio State University and completed his fellowship training in physiology and biophysics at the University of Illinois. He has published 98+ peer-reviewed journal articles and serves as a reviewer for 26+ renowned medical journals. He has been listed in "Who's Who in America" for science and engineering and lectures nationwide. Currently, he is a professor of pharmaceutical science and research and the director of pharmacology and toxicology at a major university. He is also the director of the Center for Diagnostic Nanosystems and the associate director of the Cell Differentiation and Development Center at the same institution. Additionally, he is the biological sciences laboratory supervisor at another major university.

This highly qualified psychiatric pharmacology expert received a BS in Bacteriology from the Univeristy of California Los Angeles (UCLA) and earned his doctor of pharmacy (Pharm.D.) at the University of Southern California (USC). He had a National Institute of Mental Health (NMH) training fellowship in Psychiatric Pharmacy at the University of Nebraska Medical Center in Omaha, and was recruited to join the faculty of the highly-ranked The University of Texas at Austin College of Pharmacy. He is Board Certified in Psychiatric Pharmacy (BCPP) by the Board of Pharmaceutical Specialties. He serves on the Board of Directors for the College of Psychiatric and Neurologic Pharmacists Foundation and is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP). During his 37 years career, this expert has provided clinical care and education in a variety of settings and treatment roles. He teaches didactic and experiential courses for Pharm.D. students and graduate courses for MS and PhD post-Pharm.D. students. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at San Antonio State Hospital (SASH) that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH. This expert continues to publish scholarly articles and is regularly invited to do scholarly and lay presentations around the country on a variety of pharmacy and mental health related topics. He was the Senior Founding Editor for a major mental health publication. He edited Psychopharmacology Update newsletter from 1998-2002, and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He has received several awards reflecting his accomplishments as a clinician, teacher, and researcher.

This highly qualified expert earned his BS from George Fox University and PhD from University of California- Los Angeles. He completed a postdoctoral fellowship at The Scripps Research Institute. He is actively involved in research and education; to date he has 60+ original peer reviewed articles/ abstracts. Currently, he is an Assistant Professor of Pharmacology at a major university affiliated medical center. He has been trained in the study of drug discovery and taught on Molecular Pharmacology, Drug Discovery, Molecular Signaling/Transduction for the past few years at two medical schools. His research work includes collaborations with discovery teams to design new drug strategies, synthesize novel drugs, evaluate them in cell culture models, then evaluate their efficacy, side effect profiles, pharmacokinetics, and toxicology in animal models, all with the goal of developing new drugs for human treatment. Most of his research and drug development work is centered on developing new opioid and cannabinoid drugs for chronic pain, cancer treatment, and similar diseases.

This expert has served the Drug Enforcement Administration for 21 years before entering the private sector. He gained a BA in law enforcement administration from Youngstown State University and was a state trooper for the Maryland State Police for 7 years before joining the DEA. At the DEA, he investigated international and domestic crime organizations, seizing millions of dollars in drug-related assets. This expert has been decorated numerous times and has been honored by the Attorney General for his service.

This highly experienced expert in drug discovery and drug development earned his PhD in Pharmacology from Yale University and thereafter completed a postgraduate fellowship at the University of Michigan. He previously served as the Chief Scientific Officer of Adherex Technologies, International Vice President of Cancer Research at Glaxo Wellcome (now GSK) and Associate Division Director of Experimental Therapy at Burroughs Wellcome. He is a member of the American Chemical Society, the American Association for Cancer Research, and the American Society of Clinical Oncology. He has extensive experience in preclinical and clinical research and legal consulting.

This expert in Pharmaceutical R&D has worked with data confidentiality protocols from the perspective of both a leading research scientist and an industry consultant. He earned his PhD in Pharmaceutical Science following a BS in Pharmacy and a BS in Biology from the University of South Carolina. He is a member of multiple professional societies, has published multiple peer-reviewed manuscripts, and holds 4 patents in pharmaceutical technologies. The expert formerly served as a Senior Principal Scientist at Pfizer and as an Assistant Professor of Pharmacy at South University in Georgia. He currently serves as a pharmaceutical consultant for a private firm and as president of a second private consultancy in California.

This qualified expert has extensive experience in the training, policies, and procedures involved in drug and alcohol testing. He earned his BS from the University of Central Florida and is currently a JD candidate at Florida A&M University. This expert is certified by the Drug and Alcohol Testing Industry Association as a designated employer representative. He is active in his field as a member of the Drug and Alcohol Testing Industry Association and the National Drug and Alcohol Screening Association, as well as being an author of journal articles about drug and alcohol testing. This expert currently serves as the co-founder and a corporate trainer for a drug and alcohol testing training company in Florida.

This highly-qualified expert has extensive experience with DEA suspicious order monitoring, as well as opioid and other controlled substance regulations. He earned his BS from Great Lakes University and his MS from Everest University, where he graduated summa cum laude. He is a member of the National Association of Drug Diversion Investigators and the International Health Facility Diversion Association. He formerly served as a state trooper in the Alaska Department of Public Safety and a member of the narcotics detective federal task force at Rapides Parish Sheriff's Office. He later worked as a chief health and safety investigator at MAI LLC, a physical security contractor at the US Department of Homeland Security, and the director of regulatory compliance at Miami-Luken. He is currently a president and CEO at a private consulting company in OH.

This expert is a well qualified and experienced drug and alcohol treatment professional. He completed his BA at SUNY, and his MS in clinical mental health counseling and MBA at UNLV. He is a certified addictionologist and a licensed alcohol and drug counselor. He is also active in the field as a member of the State of Nevada Association for Addiction Professionals and serves on the Governor’s Substance Abuse Working Group. He previously was the president and chief operating officer of Sierra Health Services, and was the president and co-founder of an addiction treatment facility called Resolutions. He currently is the regional vice president for a residential drug treatment company in Nevada.

This highly-qualified expert has extensive experience with pharmaceutical formulation development, as well as transdermal, topical, and controlled release drug delivery. He earned his BS in pharmaceutical science from Sandar Patel University before earning his MS and PhD in pharmaceutical science from Long Island University. This expert is active in his field as a member of the American Association of Pharmaceutical Scientists and holds a patent related to transdermal drug delivery. He formerly held roles in formulation development at Lincoln Pharmaceutical, Torrent Pharmaceuticals, and Apex Pharmaceuticals, and served as an assistant research scientist at Transdermal Research Pharm Laboratories. This expert is currently a principal scientist at a pharmaceutical laboratory in New York.

This highly-qualified expert has 14 years of experience in the field of biopharmaceutical development, having earned her BS in biology from the University of North Carolina and her PhD in genetics from the University of California at San Francisco. Her work focuses on drug development with a particular focus on gene and cell therapies, including those with the following elements: AAV, Adenovirus, CRISPR, Zfn, Endonuclease, CAR-T, mRNA, LNP, Lentivirus, HSPC. She has worked in positions such as principal consultant for Halloran Consulting Group, the founder and CEO of Tremont Therapeutics, the senior director of Shire PLC, and the executive director of CRISPR Therapeutics. She is also involved in research in her field as an author of several scientific articles. This expert currently works as the principal at a drug development consulting company in Massachusetts.

This qualified expert has nearly a decade of board-certified experience in his field. He earned his undergraduate degree in premedical education from the Adamjee Government Science College and his MD from the Dow Medical College in Pakistan. He then worked as an administrator, medical officer, and house staff general surgeon in the Civil Hospital of Karachi. He then completed a residency in internal medicine at the University of Texas Medical Branch, Galveston before going on to complete a prestigious fellowship in hematology and oncology from Albert Einstein College/Montefiore Medical Center. This expert is triple board certified in internal medicine, hematology, and medical oncology. He is very active in his field as a member of multiple professional societies including the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the American Association of Cancer Research, the American Society of Hematology, and the American Society of Clinical Oncology. In addition, this expert has published over 40 peer-reviewed articles. Formerly, this expert served as a physician in hematology and oncology at the Greater Washington Oncology Associates and was the director of clinical oncology at Medimmune/AstraZeneca. He also was a clinical instructor for internal medicine residents at Prince George Hospital. Currently, this expert is a clinical program lead for a biotechnology company and he is an independent practicing physician in hematology and oncology.

This accomplished expert received his BA in Biology from the State University of New York at Buffalo and his DO at the New York College of Osteopathic Medicine. He completed his fellowship in Pediatric Anesthesia at the Children's Hospital of Philadelphia, is board certified in Pediatrics, Anesthesiology, and Pediatric Anesthesiology, and is certified in Advanced Cardiac Life Support and Pediatric Advanced Life Support. He is an active member in the International Anesthesia Research Society and the Medical Director of the Malignant Hyperthermia Association of the United States, and the Medical Director of the Institute for Safe Medication Practices. This expert is also currently a member of the FDA's Anesthesia and Analgesia Drug Advisory Committee. His research focuses on medication safety, malignant hyperthermia, and many different aspects of pediatric anesthesia safety. Formerly, he was the Chief of Pediatric Anesthesia at the University of Rochester, and an attending Anesthesiologist at Strong Memorial Hospital. Currently, he is a professor of Pediatrics and Professor of Anesthesiology & Critical Care and Pediatrics at a prestigious university, as well as an attending anesthesiologist at a children's hospital in Pennsylvania.